[go: up one dir, main page]

AR046937A1 - Proteina nmb0928 y su uso en formulaciones farmaceuticas - Google Patents

Proteina nmb0928 y su uso en formulaciones farmaceuticas

Info

Publication number
AR046937A1
AR046937A1 ARP040104482A ARP040104482A AR046937A1 AR 046937 A1 AR046937 A1 AR 046937A1 AR P040104482 A ARP040104482 A AR P040104482A AR P040104482 A ARP040104482 A AR P040104482A AR 046937 A1 AR046937 A1 AR 046937A1
Authority
AR
Argentina
Prior art keywords
formulations
inducing
nmb0928
protein
vaccine
Prior art date
Application number
ARP040104482A
Other languages
English (en)
Inventor
Negrin Yasser Perera
Feyt Rolando Pajon
Nieto Gerardo Enrique Guillen
Garcia Gretel Sardinas
Nunez Lazaro Hiram Betancourt
Serra Lila Rosa Castellanos
Diaz Darien Garcia
Perez Olivia Niebla
Menendez Evelin Caballero
Blanco Isaac Gonzalez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of AR046937A1 publication Critical patent/AR046937A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Uso de un antígeno vacunal aplicado de manera preventiva o terapéutica contra enfermedades bacterianas, virales, cancerosas, o de otro origen. El objetivo técnico que se persigue es el desarrollo de formulaciones capaces de elevar el espectro protector de las vacunas existentes y extenderlo contra diferentes patogenos. Para lograr este objetivo se aislo e identifico la proteína NMB0928 como componente de las preparaciones de membrana externa de Neisseria meningitidis, capaz de inducir actividad bactericida. Adicionalmente, se clono y expreso el gen codificante para la proteína NMB0928, la cual se purifico evaluándose luego su inmunogenicidad en biomodelos animales. El secuenciamiento de genes homologos evidencio, por su elevado grado de conservacion, su alto valor como antígeno inductor de una respuesta inmune cruzada cuando es presentado por diferentes vías. Las formulaciones resultantes son aplicables en la industria farmacéutica como formulaciones vacunales para uso humano.
ARP040104482A 2003-12-03 2004-12-01 Proteina nmb0928 y su uso en formulaciones farmaceuticas AR046937A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2002008620030286A CU23236A1 (es) 2003-12-03 2003-12-03 PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P

Publications (1)

Publication Number Publication Date
AR046937A1 true AR046937A1 (es) 2006-01-04

Family

ID=40091627

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104482A AR046937A1 (es) 2003-12-03 2004-12-01 Proteina nmb0928 y su uso en formulaciones farmaceuticas

Country Status (16)

Country Link
US (1) US20070128230A1 (es)
EP (1) EP1693379B1 (es)
KR (1) KR20060124625A (es)
CN (1) CN100549027C (es)
AR (1) AR046937A1 (es)
AT (1) ATE456573T1 (es)
AU (1) AU2004294377A1 (es)
BR (1) BRPI0417334A (es)
CA (1) CA2547537A1 (es)
CU (1) CU23236A1 (es)
DE (1) DE602004025377D1 (es)
NO (1) NO20063017L (es)
NZ (1) NZ547521A (es)
RU (1) RU2335505C2 (es)
WO (1) WO2005054282A1 (es)
ZA (1) ZA200604492B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23549A1 (es) * 2005-12-29 2010-07-20 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas que contienen la proteína nma0939
CU23572A1 (es) * 2006-03-31 2010-09-30 Ct Ingenieria Genetica Biotech Composición farmacéutica que comprende la proteína nmb0938
CU23575A1 (es) * 2006-03-31 2010-09-30 Ct Ingenieria Genetica Biotech Composición farmacéutica que comprende la proteína nmb0606
HRP20240433T1 (hr) 2016-09-02 2024-07-05 Sanofi Pasteur, Inc. Cjepivo protiv neisseria meningitidis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4219821A1 (de) * 1992-06-17 1993-12-23 Boehringer Mannheim Gmbh Spezifischer Nachweis von Neisseria Gonorrhoeae
CU22559A1 (es) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
EP2261350A3 (en) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
GB9911692D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic combinations
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
PT2275552E (pt) * 1999-10-29 2015-12-07 Glaxosmithkline Biolog Sa Péptidos antigénicos de neisseria
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens

Also Published As

Publication number Publication date
WO2005054282A1 (es) 2005-06-16
DE602004025377D1 (de) 2010-03-18
CN1890261A (zh) 2007-01-03
BRPI0417334A (pt) 2007-03-27
CN100549027C (zh) 2009-10-14
KR20060124625A (ko) 2006-12-05
NO20063017L (no) 2006-09-01
EP1693379B1 (en) 2010-01-27
EP1693379A1 (en) 2006-08-23
AU2004294377A1 (en) 2005-06-16
RU2006123414A (ru) 2008-01-10
CU23236A1 (es) 2007-09-26
CA2547537A1 (en) 2005-06-16
RU2335505C2 (ru) 2008-10-10
US20070128230A1 (en) 2007-06-07
NZ547521A (en) 2009-07-31
ZA200604492B (en) 2007-05-30
ATE456573T1 (de) 2010-02-15

Similar Documents

Publication Publication Date Title
NO20111324A1 (no) Rekombinant MVA-virus
NO20054608L (no) Influensavirusvaksine
CY1118503T1 (el) Αντιμικροβιακο πεπτιδιο και συνθεσεις αυτου
CY1117757T1 (el) Τροποποιημενες πρωτεϊνες rsv f και μεθοδοι χρησης τους
AR083561A1 (es) Preparacion de una construccion antigenica
WO2007022425A3 (en) Influenza recombinant subunit vaccine
EP2228072A4 (en) CANCER VACCINE COMPOSITION
BRPI0416796A (pt) compostos orgánicos
CY1111916T1 (el) Εμβολιο ζωντανου εξασθενημενου ροταϊου για χορηγηση απο του στοματος
CY1117290T1 (el) Εμβολιο φυματιωσης και μεθοδος χρησης αυτου
AR046937A1 (es) Proteina nmb0928 y su uso en formulaciones farmaceuticas
DE60336588D1 (de) Verbesserte anthraximpfstoffe und abgabeverfahren
CY1107560T1 (el) Ζωντανα εξασθενημενα βακτηρια για χρηση σε εμβολιο
TW200505475A (en) Avian E. coli vaccine for protection against colibacillosis
MX395737B (es) Vacuna oral contra enfermedades respiratorias de ruminantes que contiene polivinilpirrolidona.
WO2003101482A3 (en) Liposome vaccine formulations for fin-fish
AR047263A1 (es) Proteina nmb1125 y su uso en formulaciones farmaceuticas
CU23435A1 (es) Proteína nmb2134 y su uso en formulaciones farmacéuticas
CU23419A1 (es) Proteína nmb0088 y su uso en formulaciones farmacéuticas
BR112014007491A2 (pt) sequências de aminoácidos para o controle de patógenos
AR046921A1 (es) Metodo para la incorporacion de antigenos en vesiculas de membrana externa de bacterias y formulaciones resultantes
AR060796A1 (es) Composicion farmaceutica que comprende la proteina nmb0938
DE602005021873D1 (de) Neues impfstoffadjuvans und dessen herstellung und verwendung
CU23575A1 (es) Composición farmacéutica que comprende la proteína nmb0606
CU23528A1 (es) Composición farmacéutica que comprende la proteína nmb0848

Legal Events

Date Code Title Description
FB Suspension of granting procedure